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Abstract 
 
The ability to extrapolate nutritional intervention data from experimental rodent models 
to humans requires standardization of dietary design. The inability to translate the level of 
nutrients from animal models to humans has contributed to contradictory findings between 
species. It is hypothesized that dietary linoleic acid (LA) promotes chronic and acute diseases by 
enriching tissues with arachidonic acid (AA), its downstream metabolite. However, levels of LA 
in rodent diets are notoriously erratic making interspecies comparisons unreliable. Therefore, the 
ability to extrapolate the biological effects of dietary LA from experimental rodents to humans 
necessitates an allometric scaling model that is rooted within a human equivalent context. To 
determine the physiological effect of dietary LA on tissue AA, a mathematical model for 
extrapolating nutrients based on energy was designed to mimic human equivalent doses. 
C57BL/6J mice were divided into 9 groups fed a background diet equivalent to that of the US 
diet (including LA, ALA, AA, EPA, DHA) with supplemental doses of LA (up to 2.3x) or AA 
(up to 5x). Changes in the phospholipid fatty acid compositions were monitored in plasma and 
erythrocytes and compared to data from humans supplemented with equivalent doses of LA or 
AA. Increasing dietary LA had little effect on tissue AA, while supplementing diets with AA 
significantly increased tissue AA levels, recapitulating results from human trials. Thus, 
interspecies comparisons for dietary LA between rodents and humans can be achieved when 
rodents are provided human equivalent doses based on differences in metabolic activity as 
defined by energy consumption. 
 
List of abbreviations: 
 ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid 
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Introduction 
 
The consumption of dietary fat and the incidence of cardiovascular disease, inflammation,  
and cancer have been evolving concepts of nutrition since Burr and Burr‟s 1929 discovery of fat 
as a essential component of the diet [1]. Various animal studies have examined the role of 
polyunsaturated fatty acids (PUFAs), particularly n-6 fatty acids, for their functional role in 
tissues and for their implication in disease prevention.  However, the ability to extrapolate 
nutritional intervention data from experimental rodent models to humans remains a multifaceted 
problem. The inability to translate the level of nutrients from animals to humans along with the 
lack of standardization in dietary design, have contributed to contradictory results often observed 
between the two. Specifically, inappropriate background doses of linoleic acid (LA, 18:2n-6) 
have been proposed to benefit cancer, inflammation, and atherosclerosis [2-5]. Current research 
suggests a growing concern that overconsumption of LA, the precursor to arachidonic acid (AA, 
20:4 n-6), is responsible for the increased predisposition to disease [6-7]. This study intends to 
verify a mathematical model for formulating rodent diets that will more closely mimic the typical 
human diet and human responses. The following questions will be addressed: 
 
1. What is the biological impact of n-6 fatty acid, LA, as a metabolic precursor for AA? 
2. What methodological improvements can be made in relevant dosing of n-6 fatty acids in rodent 
studies that will allow for standardization of dosing between animal models and human data 
across different research designs? 
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Part I 
 
 
Overview 
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Abstract 
  
 In the absence of other n-6 PUFAs (including dietary AA), dietary LA is the sole 
contributor to tissue AA. Following consumption, LA is desaturated and elongated to AA. It is 
hypothesized that robust downstream metabolism of LA to AA benefits cancer, inflammation, 
and atherosclerosis; however dietary composition and dosing of n-6 PUFAs among animal 
research is highly variable. As such, rodent dietary design is of immense importance in the field 
of nutrition research, not only in determining this relationship, but as a way to assess the 
translational ability of individual dietary constituents, through appropriate dosing of nutrients, to 
physiological effects observed in humans consuming similar levels of nutrients. Currently, there 
have been only a few attempts to standardize the levels of nutrients in a rodent diet to have 
human relevance. A random search of the literature supports this lack of standardization in 
dietary design and dosing of LA. The concern governing the heterogeneity of rodent dietary 
designs ultimately makes it challenging to extrapolate the findings to humans with a level of 
confidence. Therefore, investigating appropriate scaling measures for interspecies comparisons is 
critical. Establishing a model that provides standardization and a hierarchical approach to 
designing diets seems pressing. If the ultimate goal is to translate findings to humans, identifying 
allometric scaling models is fundamental for all disciplines.  
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REVIEW OF THE LITERATURE 
1.0  Overview of Omega-6 Fatty Acids 
Description 
 
Fatty acids are denoted by straight chain hydrocarbons possessing a carboxyl (COOH) group 
at one end and a methyl (CH3) group at the other. N-6 fatty acids are polyunsaturated lipid 
compounds that consist of a hydrocarbon skeleton and classified by the location of the first 
double bond on the sixth carbon from the methyl end [8].  Each double bond is separated by a 
methyl group, a process termed methylene-interrupted, which provides structural stability but the 
potential for oxidation.  LA and AA are the two predominant n-6 PUFAs. Since humans lack the 
ability to synthesize fatty acids with double bonds greater than the ninth carbon from the 
carboxyl end; these PUFAs are considered essential, indispensible, and must be included in the 
diet [8-9].  Additionally, LA is an essential component of ceramides involved in maintenance of 
the transdermal water barrier of the epidermis and both LA and AA are required as precursors for 
eicosanoid production [10-11].  
 
Molecular Structure 
 
 
arachidonic acid (20:4n-6) 
 
Figure 1. The molecular structure of LA and AA, derived from Laura Jones‟s Thesis, 2005. 
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Dietary Sources 
 Foods rich in LA include most vegetable oils (i.e., sunflower, safflower, evening 
primrose, sesame, corn and soy) [8, 12], animal products (i.e., chicken, pork, steak) and dairy 
products (i.e., eggs, cheese)  [13]. AA is found exclusively in animal products (i.e., beef ribeye, 
chicken, eggs, pork loin, turkey, fish) [14]. A comparison of food sources high in LA and AA is 
depicted in (Table 1).   
 
 
Western Consumption of LA 
 
 Dietary LA is the most abundant PUFA in Western consumption [13-15]. Median intakes 
of LA are held respectively between 11–17 g/day for women and men (contributing to ~4-10% 
energy based on a 2,000 kcal/d diet) [15-17]. Notably, LA recommendations are 10 to 100 times 
higher than alpha-linolenic acid (ALA) and other essential long-chain fatty acids [15], (Table 2). 
Hence, LA represents 90% of n-6 fatty acids in the Western diet [12]. The rise in LA-containing 
oils (i.e., corn, sunflower, safflower, soybean) and the shift in the n-6 to n-3 ratio mirrors the 
growth of the innovative vegetable industry [18]. 
 
Table 1. Dietary sources of linoleic acid and arachidonic acid [14] 
Food Item Linoleic acid Arachidonic acid 
                                          mg fatty acid/100g cooked food 
Chicken thigh 838 ± 27 121 ± 6 
Chicken breast 272 ± 17 83 ± 8 
Egg (whole) 1884 ± 183 239 ± 21 
Beef rib eye 320 ± 51 77 ± 14 
Canned tuna 25 ± 2 33 ± 4 
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LA Deficiency 
 
The severity of dermatitis, skin barrier dysfunction, and cutaneous inflammation are 
associated with the depletion of essential n-6 PUFAs at levels required in the diet; observed in 
both rodent and human studies [1, 19]. Dietary consumption of LA at 1-3% of energy is 
sufficient for AA synthesis and turnover [12, 20]. Biochemical and dysfunctional consequences 
of n-6 PUFA deprivation in rodents under normal n-3 PUFA concentrations, further explain the 
essentiality in a tissue specific manner (i.e. reductions in brain, heart, liver, etc) [21]. 
Interestingly, n-6 PUFA deprivation is associated with increased concentrations of n-3 PUFAs 
and monounsaturated fatty acids (MUFAs) for maintenance of adequate membrane fluidity and 
body function [21]. Membrane saturation requirements of both n-3 and n-6 PUFAs are therefore 
essential for establishing an appropriate dietary design in both humans and rodents.  
 
Availability to Human Tissues 
Dietary consumption of LA above 2-3% of energy in humans is not reportedly 
accompanied by an increase in AA plasma/serum and erythrocytes lipid levels [12, 22-25]. In 
human peripheral tissues, increasing dietary LA from 4% to 18% of energy resulted in lower 
levels of AA in the cholesterol esters and phospholipid fractions of hyperlipemic subjects [26]. 
Adam and colleagues found significant increases in LA plasma cholesterol esters and HDL-
phosphatidylcholine when LA was supplemented up to 20% of energy compared to a fat-free 
diet.  Tissue levels of AA significantly decreased in the high dietary LA groups (4% and 20% of 
energy) while increasing in the fat-free group [20]. These results are indicative of the influential 
power of dietary LA to increase tissue LA, but not AA in this human study. Interestingly, neither 
group given differential levels of dietary LA (4% and 20% of energy) increased prostaglandin 
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(PG) synthesis [20]. These findings are in agreement with the concept that desaturation of fatty 
acids regulates cell fluidity and does not favor increased PG formation via the AA cascade when 
fed adequate amounts of LA (at least 1-3% of energy) [12]. Nonetheless, the relationship 
between LA and AA in rodents has yet to mimic the responses observed in humans. A 
perspective look at LA in the diet of both rodent and human studies may provide more of a 
consensus on the biological effects of LA-derived foods and the relationship to acute and chronic 
diseases.  
 
 
 
Table 2. Suggested adequate intake and recommended intakes of n-6 polyunsaturated fatty 
acids versus current estimated consumption in the United States [27] 
  
Linoleic Acid 
 (LA) 18:2n-6 
 
Linolenic Acid  
(ALA) 18:3n-3 
National Academy of Sciences 
(AI) 
   (DRI, 2002) 6.4% energy 
 
0.6% energy 
Men 17 g/d @ 2400 kcal 
 
1.6 g/d @ 2400 kcal 
Women 12 g/d @ 1700 kcal 
 
1.1 g/d @ 2400 kcal 
Recommendations [27] 
   All adults 5-8% energy 
 
0.75% energy 
 
~15 g/d @ 2000 kcal 
 
~1.7 g/d @ 2000 kcal 
Current Mean Estimated Intakes 6.3% energy 
 
0.75% energy 
[28] 14 g/d @ 2000 kcal 
 
1.7 g/d @ 2000 kcal 
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Western Consumption of AA 
 
 AA is arguably the most important fatty acid associated with membrane phospholipids 
and is involved in eicosanoid production, and cellular proliferation and differentiation [14-15]. 
While dietary LA is a contributor to tissue AA, variations in LA consumption, specifically LA 
intakes above 2% of calories in humans, were reported to have only minimal alterations on 
changes in the content of AA in phospholipids of human neutrophils [24]. Additional human 
clinical trials report dietary variations of LA from (3%-20% of energy) did not significantly 
increase tissue AA concentration [22, 25]. A human tracer study that examined median fractional 
turnover rate of LA, found as little as 0.3% to 0.6% of LA was converted to AA [29]. In rodents, 
the in vivo conversion of supplemented C18 fatty acids (i.e., LA, ALA) to downstream end-
products (i.e., AA, DHA), measured by stable isotopes, was found less efficient when compared 
to C20 fatty acids, possibly indicating the control of ∆-6 desaturase in regulating metabolic 
activity when dietary PUFA intake is high [30].  
The consumption of AA-derived foods, however, significantly impacts tissue AA 
concentrations in both animal studies [31-33] and human trials [34]. Estimated median intake of 
AA in humans is 100-500 mg/day (~0.9 % energy), respectively, notably lower than LA. Due to 
the unreliability of food composition databases for highly unsaturated fatty acids (HUFAs), the 
accuracy of daily AA intake is still unclear [13].   
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Digestion, Absorption, and Transport 
 The composition of cellular membranes are regulated by both genetic and environmental 
factors, in particular, dietary fat profiles [35]. Dietary n-6 fatty acids are consumed in the form of 
triglycerides and phospholipids found in food. The majority of dietary lipids ~98% are found as 
triacylglycerols (TAG) which contain three fatty acids esterified to a glycerol backbone [36]. N-6 
fatty acids, LA and AA, are located in the sn-2 position of the triglyceride molecule [11].  While 
these fatty acids have a specialized location on the TAG they still follow the same digestion, 
absorption, and transport as all other lipid components.  
 Digestion of dietary lipids begins in the stomach where short and medium chain fatty 
acids are hydrolyzed by gastric lipase, an enzyme secreted by the gastric mucosa [36-37].  
Gastric lipase works in the stomach under acidic conditions to cleave medium chain fatty acids 
into diacylglycerol (DAG) and free fatty acids (FFAs) [37].  Some short and medium chain fatty 
acids can be readily absorbed through the stomach, while longer fatty acids must be broken down 
in the small intestine.  Fat digestion continues through the action of pancreatic lipase and 
colipase at the interface of the oil and aqueous phase [37]. Working mainly on the sn-1 and sn-3 
position of the TAG, pancreatic lipase releases 2-monoacylglycerol (MAG) and FFAs, important 
for further emulsion by the action of bile salts [37]. The presence of bile in the lumen of the 
intestine increases the solubility of lipolytic products in the aqueous intestine to emulsify the 
intestinal contents for formation of micelles [38]. The components of the micelle are transported 
into the enterocyte for reesterification into TAGs, phospholipids, and cholesterol [36]. 
Translocation across the membrane occurs by both passive diffusion and carrier-mediated 
transfer [38]. After the reassembly within the enterocyte, triglycerides and phospholipids are 
combined with apolipoproteins to form chylomicrons which can then enter the lymphatic 
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circulation as TAG-rich lipoproteins. Once in the circulation, lipoprotein lipase works similarly 
to pancreatic lipase, in that it hydrolyzes the TAG-rich lipoproteins into one monoacylglycerol 
and two FFAs for tissue utilization [36].  Glycerol and chylomicron remnants are subsequently 
cleaved by the liver. 
 
Biomarkers of Dietary Fat  
Lipid metabolism is highly altered by variations in dietary intake that work to maintain a 
stable membrane composition. Daily fluctuations in fatty acids reflect the competitive nature of 
n-3 and n-6 PUFAs, thus providing useful information about average tissue maintenance [39]. 
The assessment for fatty acid composition in various compartments such as adipose tissue (long-
term), erythrocytes (medium-term), and plasma or serum (short-term) enable stable readings over 
a given period of time [40]. A common fatty acid biomarker for human and rodent studies is the 
erythrocyte (RBC) membrane. RBC membranes vary with environmental factors, oxidative 
stress, and diet [41]. It is held that erythrocyte fatty acid measurements more accurately correlate 
with dietary intake than do measurements of serum FA‟s [41]. While RBC turnover (120 day 
lifespan) provides a better marker of long-term fat intake compared to plasma, phospholipids, 
TAGs, this view is not consistently held across all research [42]. Alternatively, plasma lipid 
fractions provide the most accurate dietary reflection of short-term fatty acids, particularly those 
fatty acids after a meal [42]. It has been observed that maximal saturation of RBCs and plasma 
TAGs was achieved within 14 days [42]. This is important in determining the length of a human 
or animal dietary intervention study to ensure that fatty acids have reached their maximal 
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threshold in tissues. Additionally, choosing the most appropriate biomarker accessible for 
interspecies comparisons is an essential component of experimental design. 
 
1.1   Conversion of LA to Downstream Metabolites 
 It is well established that mammals lack the ability to desaturate fatty acyl chains beyond 
the ∆ 9 carbon, therefore making consumption of precursor long-chain fatty acids, such as LA, 
an essential component of the diet [43].  Following consumption, LA can participate in 
oxidization, incorporation into membrane phospholipids, storage in TAGs, or convert to long-
chain metabolites [13]. PUFAs, both n-3 and n-6 are synthesized by membrane-bound desaturase 
families; ∆-6 and ∆-5 desaturases [43]. The conversion of LA to its downstream metabolites is 
first catalyzed by ∆-6 desaturase, also known as the rate-limiting step for enzymatic PUFA 
biosynthesis [35]. All desaturases require molecular oxygen for addition of intermittent double 
bonds along the substrate in a way that maintains the methylene-interrupted distribution [44]. 
Elongases which are enzymes responsible for adding two carbons to the carboxylic end of the 
fatty acid, help regulate metabolic fate and degree of unsaturation. The ∆-5 desaturase which 
places a double bond at the ∆-5 position of the 20-carbon fatty acid is responsible for the final 
conversion of LA to its preferred form as AA in tissues [43]. In humans, further desaturation of 
AA is limited by the body‟s preference to maintain a precise quantity of AA in cells and tissues 
[10] (Figure 1).  
The majority of LA conversion to long-chain metabolites, with the help of elongases and 
desaturases, is presumed to take place in the endoplasmic reticulum [45]. However, biosynthesis 
of PUFAs is indeed a coupled process between the endoplasmic reticulum and β-oxidation in 
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peroxisomes during final conversion steps [46-47].  Intermediates can either be incorporated into 
phospholipids or become the substrates for further downstream conversion [16]. LA may 
additionally participate in low-density lipoprotein (LDL) clearance and decreased LDL 
production important in maintaining adequate cholesterol levels [27]. Importantly, LA appears to 
hold a membrane “threshold” requirement affected by various environmental (i.e. diet) and 
genetic factors (as reviewed by [27]). Furthermore, exaggeration of plasma and tissue fatty acid 
composition of specific fatty acids (i.e., AA, EPA, DHA) may result if LA levels fall below the 
threshold of essentiality (as reviewed by [27]). Additionally, LA and AA are important for 
eicosanoid signaling, pinocytosis, ion channel modulation, and gene expression regulation [43].  
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Figure 2. Omega-6 fatty acid metabolism 
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Metabolism of Arachidonic Acid 
 AA is considered one of the most abundant PUFAs involved in membrane phospholipids 
and production of eicosanoids [33]. The initial step in eicosanoid synthesis is translocation of 
phospholipase A2 (PLA2) to the cell membrane by a receptor-mediated influx of Ca
2+ 
ions [48]. 
Hydrolysis by phospholipase A2  (PLA2) cleaves the ester bond of AA at the sn-2 position, 
generating a FFA and a lysophospholipid [49]. Free AA is a precursor for synthesis of PGs in the 
conversion through cyclooxgensase (COX) and lipoxygenase (LOX) pathways to generate 
eicosanoids (i.e. PGs and leukotrienes) involved in the inflammatory process [8, 48-49] (Figure 
2). An imbalance between high intakes of LA and eicosanoid production through AA 
metabolism has been proposed to promote atherosclerosis, tumor growth, and immune-related 
pathologies [50]. Therefore, targeting tissue AA content for regulation of eicosanoid expression 
is a growing topic of interest [10, 33]. Like LA, there appears to be a membrane “threshold” 
requirement of AA in tissues [15]. However, dietary alterations of LA to control AA metabolism, 
as proposed by many authors, would require drastic changes in the Western diet (i.e. elimination 
of nearly all animal and plant products) [15]. Furthermore, dietary LA within the context of a 
typical human diet has not been found to increase the risk of acute and chronic disease states 
through AA metabolism [15, 51-52].  
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Figure 3. Downstream metabolism of AA 
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1.2   Overconsumption Concerns Governing LA 
 The role of n-6 PUFAs in disease prevention is an unrelenting topic of interest and 
controversy. Relative changes in the course of evolution have been shaped by a variety of genetic 
and environmental changes impacting the modern-day diet. Paleolithic dietary habits (45,000 
years ago) were comprised mainly of fish, wild plants, and nuts and seeds that were much lower 
in total fat than the current Western diet;  however, there is no available data on the health status 
of these predecessors [16, 28]. Moreover, the ratio of n-6 and n-3 fatty acids was once thought to 
be 1:1 [28, 53-54]. The increase in technological advancements and the food supply has shifted 
this ratio toward an increased consumption of n-6 fatty acids at the expense of n-3; proposed to 
be 15:1 and 20:1 [6, 11, 16, 54].  This shift, however, mirrors the growth of the innovative 
vegetable oil industry [28].  In all actuality, the mean ratio of n-6 to n-3 fatty acids in the United 
States is held respectively at ~9.8:1 [28]. Since it has been proposed that dietary fatty acids are a 
reflection of membrane fatty acid composition, considerable speculation of the n-6 to n-3 ratio 
have arisen for implication in various diseases [53]. The concern of increased dietary n-6 PUFAs 
lies in the production of AA, a central pathway for eicosanoid synthesis.  Simopoulos and 
colleagues propose “a diet rich in omega-6 fatty acids shifts the physiological state to one that is 
prothrombotic and proaggregatory, with increases in blood viscosity, vasospasm, and 
vasoconstriction and decreases in bleeding time [54].” The common term for n-6 PUFAs, as 
consistently noted by many authors, is seamlessly interchanged with dietary LA. This generic 
term, while correct, negates the differential tissue specific effects of individual n-6 PUFA 
metabolites.  
Higher dietary n-6 PUFAs is suggestive of greater antagonist effect on n-3 PUFA 
metabolism of α-linolenic acid (ALA) and reduced cardioprotection [54-55]. Additional 
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arguments propose lower LA intakes will produce a higher n-3 index for protection against 
coronary heart disease (CHD) [56] by reducing the exposure of eicosanoid metabolism and 
inflammation [55]. However, data strongly suggests a direct inverse association of decreased LA 
and increased CHD risk [57]. Interestingly, a study by Riediger and colleagues found a diet high 
in n-6 PUFAs, relative to n-3, actually reduced plasma TG levels comparable to baseline values 
in mice [58]. Nonetheless, membrane fatty acid composition is influenced by exogenous fatty 
acids and the balance of substrates in the diet [55, 59]. 
While the n-6 to n-3 ratio has indeed increased, targeting the consumption of LA may not 
be the answer. Kris-Etherton and colleagues argue that a variation in LA intake does not 
substantially affect tissue AA levels in humans, with only ~0.2% dietary LA actually converted 
to AA in tissues [60-61].  Additional support from rodents, found dietary LA to have little effect 
on altering AA hepatic phospholipids compared to the supplementation of dietary AA which 
significantly enriched AA tissue levels [62]. One possible explanation of dietary AA 
accumulation in mice may be a result of reduced oxidation to CO2 ,with only 14% compared to 
42% from dietary LA [62] or that the accumulation of dietary AA in mice may be subject to a 
dietary experimental design that lacks one or more essential fatty acids. Nonetheless, the debate 
on the overconsumption of LA in both rodent and human studies remains inconclusive.   
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1.3   Health Implications 
Cardiovascular Health 
 Dietary profiles may provide one way for assessing the link of PUFA consumption and 
optimal heath. The American Heart Association supports an n-6 PUFA intake of at least 5-10% 
of energy for heart health (as reviewed by [60]). The „consume less‟ n-6 theory (as reviewed by 
[6]) lies in the formation of atherosclerotic plaque initiated by the accumulation of LDL and pro-
inflammatory cytokines that is believed to be driven by the competition of AA and EPA for 
metabolic conversion [8].  It is assumed that the link between PUFA consumption and 
cardiovascular disease (CVD) lies in eicosanoid regulation [8] and protection from oxidative 
damage [63]. While the n-3 index is an important marker for CHD there are other factors that 
contribute to cardioprotection [60]. Therefore, the antagonistic role of LA or AA with EPA does 
not appear to substantially lower the n-3 index [60]. Clearly this paradigm is complex and often 
misinterpreted.  
A review of the literature by Harris [57] found most data in favor of increasing dietary 
LA to decrease the risk of CHD. In humans, a meta-analysis found that n-6 PUFA intake of 10-
21% energy reduced the risk of CHD compared to individuals with lower intakes [57]. In fact, 
LA is found to be the most potent dietary fatty acid in reducing total cholesterol and LDL levels 
[64]. In a human study, feeding 25% of energy from LA over a 5 year span, there was found to 
be reduced atherosclerosis with no adverse side effects [65-66]. Salmeron and colleagues report 
that women with a mean intake of 7% of energy from LA had a significantly lower risk of type 2 
diabetes compared to those consuming less than 4% of energy from LA [67]. There is evidence 
of higher LA intakes improving insulin resistance [68] and effectively lowering blood pressure 
[69]. While many human studies demonstrate the ineffectiveness of various dietary LA doses to 
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significantly increase cardiovascular risk [27, 70], the majority of animal research and several 
human researchers continue to advocate the relationship of n-6 PUFAs and  increased 
susceptibility to disease [6, 50].  
 
Inflammation 
 Similar to CVD, LA is proposed to have pro-inflammatory activities independent of its 
role as a precursor for AA synthesis [71-72]. The lack of consensus on an appropriate biomarker 
for inflammation has left many researchers at a loss for concise comparison [17]. Since, LA is a 
substrate for two metabolically active oxidation products (i.e. leukotoxin (LT), leukotoxin diol 
(LTD)), in vitro treatment of endothelial cells with LA, LT, or LTD was found to promote 
oxidative stress responses [73].  This study would imply that LA metabolism, in part, possesses 
pro-inflammatory capabilities. The interference of n-6 PUFAs on n-3 PUFA anti-inflammation is 
a well explored topic. In a prospective human cohort, it was found that consumption of n-6 fatty 
acids did not inhibit the beneficial effects of n-3 PUFAs, and taken together, higher intakes of 
both n-6 and n-3 PUFAs were associated with the lowest inflammation [74]. Similarly, a study 
by Liou and colleagues found no significant changes in inflammatory markers when comparing 
4% to 12% of energy from LA [22]. In fact, Whelan and colleagues report that LA levels were 
significantly lower in tissues when AA was included in the diet [33]. Even when LA was 
increased by 55%, AA concentrations did not significantly change or significantly impact 
eicosanoid production [33].  
 In addition to assessing LA, dietary AA has been a central focus of the inflammatory 
process. Two human studies report no significant effect on inflammatory biomarkers with the 
addition of 1200 mg of AA/day maintaining a constant n-3 intake [75] or with the addition of 
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700 mg of AA/day [76]. In contrast, it was found that AA at ~2.4% of energy or, 11 grams 
respectively, significantly enhanced the production of PGE2 in peritoneal macrophages of 
hamsters, similar to the results found in human studies [33]. Therefore, it is perceivable that AA 
also holds a specific threshold in tissues that is affected by other fatty acids present in the diet. 
Nonetheless, AA consumed at average human intakes of 180 mg/day, respectively, seems 
unlikely to create robust inflammatory stress that could potentiate chronic diseases.  
 
Cancer 
 There is growing concern over the possible link between dietary fat, particularly animal 
fat, and cancer (i.e. breast, colon, intestinal, prostate, etc) [77-81]. Epidemiological studies have 
observed a linear relationship with increasing dietary fat and incidence of breast and colon 
cancer [79]. Like CVD and inflammation, much speculation has been placed on dietary LA 
consumption. Rogers and colleagues observed fewer colon tumors in animals fed 28% beef fat 
than the controls fed 15% corn oil (~9% energy LA), while Carroll and colleagues similarly 
found a lowered incidence of mammary tumors in animals fed beef fat versus corn oil [79, 82]. 
This would imply the pro-tumorigenic capability of dietary LA in the form of corn oil-based 
diets. Additional rodent studies have found the feeding of LA up to 14% of energy promoted the 
growth and progression of mammary tumors in mice [5]. However, in a follow-up study, no 
significant differences in tumor progression were found between mice fed the 23% corn oil diet 
(~14% of energy from LA) and mice fed the 5% corn oil diet (~3% energy of from LA) [83]. 
Buckman and colleagues demonstrated the direct stimulatory effect of LA (12% of energy) and 
oleate on the growth of mammary tumor cells; suggestive of an independent role of unsaturated 
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fatty acids and prostaglandin synthesis [2]. Conversely, Hubbard and colleagues found mammary 
tumorigenesis was enhanced by LA and was not dependent of oleic acid (18:1n-9) levels [4].  
Two opposing roles of LA on mammary tumorigenesis were observed by Lane and colleagues. 
In one experiment, 20% corn oil (~12% of energy from  LA) induced metastasis, however the 
second experiment found that 20% corn oil did not significantly affect mammary tumor 
incidence [2]. In examining lipid profiles of rodents fed corn oil, soybean oil, or palm oil, no 
consistent changes were observed in mammary tumor carcinogenesis [84]. Overall, the 
consensus on LA‟s role in mammary cancer remains inconclusive, most notably due to 
differences in experimental design. 
   The diets of rodents fed 20% menhaden oil (primarily n-3 fatty acids) versus 20% corn 
oil (~12% of energy from LA) were associated with significantly reduced pancreatic lesions [3]. 
Similarly, Roebuck and colleagues found that 20% corn oil (~12% of energy from LA) was 
associated with enhanced perimental pancreatic carcinogenesis in rats [85]. The anti-tumorigenic 
effect of n-3 PUFAs demonstrated in these studies point to the opposing role of n-6 and n-3 
PUFAs as potent oncogenic precursors based on dietary factors alone. While n-3 PUFAs are 
known for their anti-inflammatory properties [86-87] , concluding n-6 PUFAs as carcinogenic 
promoters based on the doses used in these studies may not be accurate.  In order to better 
establish the relationship between diet and disease in a rodent model, a properly scaled design 
that includes appropriate doses of nutrients, allometrically based on human DRIs, must first be 
implemented in the basic design.  
The amount of LA in background dietary designs among animal research is highly 
variable. As such, the translation of data from rodents to humans of poorly designed 
experimental models has contributed to uncertainty among the literature, noted by many of these 
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studies. Therefore, designing rodent diets considering allometric scaling factors and the inclusion 
of all human equivalent dietary components may better pinpoint LA‟s specific role in 
cardiovascular disease, inflammation, and carcinogenesis. 
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1.4   Animal Model Research  
 
Rodent Dietary Models 
  
Currently, there are three main rodent diets used by research intervention studies. These diets 
include AIN76A: 5% corn oil (CO) (59% LA, 6.6% of energy); AIN93G: 7% soybean oil (SBO) 
(54% LA, 8.3% of energy); and AIN93M: 4% SBO (54% LA, 4.8% of energy) [88] (Figure 4). 
While these diets do provide most of the essential fatty acids, they appear to be inconsistent in 
levels of LA (based on % of energy). This is of particular interest in investigating the proposed 
role of LA-derived foods on enhanced risk for chronic and acute diseases. Notably, current 
human consumption of LA is held respectively at ~6 % of energy (7-10 % of energy) [10], but 
most rodent dietary intervention studies do not use human equivalent LA doses in the 
background diet. Rodent dietary designs utilizing an inappropriate dose of LA (i.e. deficient or 
excessive) that does not correspond to human consumption or designs lacking all essential fatty 
acids may potentially heighten or exaggerate the responses in tissues [10].  
 
 
 
Figure 4.The discrepancy of LA doses of current rodent diets based on % of energy from LA 
compared to a human equivalent dose containing 6% energy from LA.  
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Rodent Designs Supplemented with LA 
A collection of rodent studies interested in the response of LA supplementation on tissue 
fatty acid composition strikingly outline the variability in animal model experimental design 
(Figure 5). The array of varying initial and supplemented doses of LA, portray the inconsistency 
of animal dietary design.  Additionally, the comparison to a human equivalent dose of ~6% of 
energy denotes the improper dosing in the background diet for interspecies comparisons. Rucker 
and Storms in 2002, propose that direct extrapolation to an adult human based on doses given to 
rodents may be in error by a factor of 10 or higher  [89]. Consequently, the overestimation of 
nutrients for  a smaller animal may lead to toxicities when extrapolated to a larger animal [89]. 
Therefore, using a standard scientific rationale for dosing may provide more consistent translatable 
findings.  
 
 
 
Figure 5. Comparison of a human equivalent dose (6% energy from LA) to initial and supplemented 
doses of LA in rodent dietary studies.  
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Table 3. The comparison of background and supplemented doses of % energy from LA and the rationale 
for experimental design are displayed among various rodent dietary studies.  
_____________________________________________________________________________________ 
________________________________________________________________________________ 
 
Study Background Energy% LA
Supplemented 
Energy% LA
Background Source of 
PUFA
Intended Outcome Rationale 
Mohrhauer et al (1962) 0
0.009, 0.02, 0.05, 
0.10, 0.18, 0.32, 
0.61, 1.26, 1.79, 
4.87
Fat-Free
To show the influence of various 
levels of LA, AA, and ALA esters 
upon FA composition in l iver 
l ipids of rats.
Based on previous studies 
comparing animals fed fat-free diets 
with those fed single levels of 
essential fatty acids.
Mohrhauer et al (1963) 0
0.08 up to 0.73 
but Supplemented 
ALA  at differing 
ratios
Fat-Free
To compare to a previous study 
feeding LA and ALA singly
Intake levels were chosen in the 
range of unstated ratios. 
Rahm et al (1964) 0
0.28, 0.97, 1.97, 
3.87, 7.57, 12.42, 
17.26
 Fat-Free 
Determine the inhibition of 
l inolenate metabolism by 
linoleate.
None
Lane et al (1985)
~5% Fat- Chow Diet (Wayne 
Lab Blox)- Distribution not 
indicated
6, 24.6 (Based on 
AIN76A)
Corn Oil
To demonstrate whether a diet 
high in PUFAs (corn oil) would 
enhance or promote DMBA 
induced mouse mammary 
tumorigenesis in mice.
Based the % energy from other 
studies showing that high corn oil  
diets change the FA composition in 
mammary cells.
Ip et al (1985)
~20% w/w Synthetic Fat 
Diet (~44% en)
4.4, 9.0,  14.3,  
26.6
Coconut oil, Corn oil
To determine the requirement of 
essential fatty acid for di-
methylbenz(a)anthracene-induced 
mammary tumorigenesis.
Based on other studies investigating 
LA as a tumor-promoter.
Roebuck et al (1986) 6 (AIN diet not specified) 2.5, 24.5 Corn oil, Coconut oil
To examine if the effect of high 
levels of unsaturated fats 
selectively stimulate carcinogen-
induced foci.
Previous investigation found the 
high fat diets are comparable in 
their effects on rat growth of 
pancreatic lesions.
Reddy et al (1988) 6 (Based on AIN76A)
28.9 (CO group), 
Additional groups 
with CO+ 
Menhaden Oil
Corn oil, menhaden oil  
(EPA, DHA, AA, LA, oleic 
acid, palmitic acid)
To investigate the efficacy of 
varying amounts of mehaden oil  
and corn oil  on colon 
carcinogenesis for determination 
of optimal dietary levels.
Based on previous studies looking 
at the combination of corn oil  and 
mehaden oil.
Sundram et al (1989)
Rodent Chow (No 
specification)
24.6 (CO group), 
23.8  (SBO group)
Corn oil, Soybean oil, 
Crude palm oil, 
Deodorized palm oil, 
Metabisulfite treated 
palm oil
To investigate the effect of 
different high palm oil diets on 
mammary carcinogenesis in 
female rats treated with DMBA.
None
Buckman et al (1989) 3 (Purina Mouse Chow) 12
Mainly safflower oil, 
Triolein, Coconut oil
To examine whether oleate, when 
added to a diet that promotes 
metastasis (12% enLA) would 
modulate the growth and 
metastasis of l ine 4526 mouse 
mammary tummors.
Based on studies in which mice 
were fed 12% energy from LA, they 
observed significantly more tumors.
N.E. Hubbard et al (1991)
Stock Diet (Purina Mouse 
Chow)
2.2, 13.2, 26.4
8:0, 10:0, 12:0, 14:0, 
16:0, 16:1n-7, 18:0, 
18:1n-7, n-9, 18:2n-6
To test whether increasing the 
dietary level of oleic acid can alter 
the level of 18:2n-6 -enhanced 
metastasis.
Based on a previous study, 
suggesting that 12% w/w (26.4% 
energy) from LA induced lung 
metastasis.
Whelan et al (1992) 4.4 (Prolab Chow Diet) 7.5
High oleic sunflower, 
Tripalmitin, 18:1n-9 
(Oleic Acid Ethyl Ester)
To evaluate the effects of dietary 
AA on hepatic tissue FA 
composition compared to results 
with those obtained from matched 
animals on LA diets.
Based on previous studies looking 
at dietary AA while controlling for 
other FA's.
Lokesh et al (1992) 6 12
Corn oil, 14:0, 16:0, 16:1, 
18:0, 18:1n-9
To investigate the use of l ipids 
with different FA compositions as 
a potential fat source for 
parenteral and enteral diets. 
Oils were selected for their wide 
differences in FA compositons. No 
rationale for doses. 
Rose et al (1993) 6 (Based on AIN76A) 4.4, 17.6, 26.4
Safflower Oil, Coconut 
Oil
To determine the effect of 3 
different levels of dietary LA intake 
on the growth of MDA-MB-435 
cancer cells in mammary fat pads 
of nude mice.
Based on previous studies looking 
at high -fat diets on the growth of 
MDA-MB-435 human breast cancer 
cell  l ine.
Rodent Dietary Designs
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Rodent vs. Man 
 Comparing rodent data to human clinical trials results in an observable difference. In 
comparing the % change of AA with increasing LA (% of energy) between 8 rodent dietary 
studies [2, 21, 33, 62, 90-93], delineates the inconsistent response of AA when LA is provided at 
doses of 0.73% to 27% of energy (Figure 6). The differences in the background dietary 
composition of these 8 rodent models explain the erratic data. The % change in AA plasma 
phospholipids with increasing LA (% of energy) in human studies does not appear to portray the 
same LA to AA relationship observed in rodents (Figure 7). Data obtained from humans indicate 
a weak correlation between both variables. This intriguing finding is indicative of the 
disconnection between rodent and human data. The large response on tissue AA fluctuation in 
the rodent models is likely the source for heightened fear governing LA conversion to AA in 
tissues. This gap in interspecies translation leads to the importance of an established rodent 
dietary model. Formulating an appropriate dietary design for comparison to human clinical trials 
will hopefully result in more comparable findings.  
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Figure 6. Rodent data comparing the % change in AA with increasing LA (% of energy) between 
8 studies [2, 21, 33, 62, 90-93]. The data represents an inconsistent response of AA when LA is 
provided at doses of 0.73% to 27% of energy. The red triangles indicate a significant value.  
 
 
 
Figure 7. Human data comparing the % change in AA (plasma phospholipids) with increasing 
LA. The positive dose responsive relationship between LA and AA observed in rodents does not 
appear to exist in humans. The red triangles indicate a significant value. Derived from Brian 
Rett‟s Thesis, 2011. 
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1.5   RELEVANT DOSING FOR ANIMAL MODELS: A SCALING APPROACH 
 
Introduction 
 
An appropriate dietary design in animal models requires proper extrapolation between 
species. Supplemental doses in rodent models must meaningfully represent normal consumption 
by humans. For proper use of animal models in nutritional interventions, a certain degree of 
thoughtfulness should precede the design. If animal models are to truly predict biological 
responses in humans, we first must examine the paradigm of interspecies comparison.    
 
History of Allometric Scaling 
Basal metabolic rate (BMR) was first proposed for describing allometric relationships 
between body mass and metabolic rate of both animals and humans [94]. BMR represents the 
minimal cost of living or energy turnover at constant body temperatures [94-95].  In 1838, Sarrus 
and Rameaux were the first to suggest a rationale for interspecies comparison. Their proposed 
theory, the Surface Law, suggested that heat loss and production based on different-sized species 
should be related to surface area rather than body mass [94]. This proportionality of BMR and 
surface area raised to the 2/3-power was accepted well into the 20
th
-century [96]. In 1916, Krogh 
suggested an empirical approach whereby BMR was related to a 0.73 power function of body 
mass [94-95]. Krogh‟s discovery led Max Kleiber in 1932, to show that metabolic rate is 
proportional to its ¾-power not to body weight alone [97]. This theory is based on the following 
equation: 
M= 70W
3/4  
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Where M is the metabolic rate in kilocalories per day and W is body mass in kilograms. This 
three-quarter power scaling of BMR is a model of comparative physiology well-accepted by 
many researchers for its widespread scaling implications [96].  In pursuit of understanding this 
power scaling exponent, West et al [98] proposed a set of principles detailed by the process of 
natural selection and sustained “hierarchical branching networks.” Scaling variation observed at 
intracellular levels and sub-cellular compartments (mitrochondria) tested in mammalian species, 
all proposed the quarter-power allometric scaling feature reflecting constraints inherent in 
genetics and energy expenditure into circulation [98]. 
 Three-quarter power scaling is one approach for interspecies comparison that may be 
implemented into current research of nutritional animal model designs. Currently there is no 
clear standardization of nutrient comparisons in animal research. Typical doses are formulated 
based on bodyweight or relative doses that maximize the intended results. Therefore, the aim of 
this project is to establish a mathematical model for interspecies evaluation, in particular (n-6) 
PUFA levels, for appropriate extrapolation to humans. In order to devise a mathematical model 
for widespread implementation in research, this model must include several components: it 
should linearize the relationship between rodent and human data; should be applicable to the 
general range of (n-6) PUFA studies; be tested on its ability to yield similar biological effects in 
animal models and humans; and be straightforward to use.  
 Body weight has previously been used as a nutritional extrapolation approach, but 
according to Rucker and Storms, direct extrapolation from a mouse to an adult human may be in 
error by a factor of 10 or more [89]. The misunderstanding in human equivalent doses (HED) has 
left a gap in allometric dose translation [99]. Therefore, Rucker and colleagues proposed 
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interspecies comparison is best expressed as a measure of metabolic body size or food intake 
[89]. Rucker‟s point is further supported in homeothermic animals, showing that mineral 
requirements are similar across species when expressed as measure of energy intake [89]. With 
these findings, we propose a model based on consideration of daily energy consumption in 
rodents and humans as a means of dose standardization.  
 
  1.6   Implication in Rodent Dietary Design 
When designing an experiment it is crucial to establish scientific rationale for experimental 
design. If the overall goal of nutritional intervention studies is to translate the results to people, a 
standardized diet appropriate for interspecies comparison must be formulated. The following 
proposal hopes to provide more consistent findings and a well-recognized background dietary 
standard for all research paradigms. 
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  1.7   Research Objectives 
 
Specific Aims  
 
 Dietary fat has been correlated with the incidence of chronic and acute conditions that are 
potentially modifiable [63, 100]. More specifically, the concern for n-6 PUFA overconsumption 
of LA appears to arise from rodent experimental models that lack appropriate design for 
comparison to humans. The primary aim of this study is to address the disconnection between 
experimental models for dietary comparison and provide a more suitable model for nutrient 
extrapolations between species.  
Our overall goal is to formulate a rodent dietary model with an appropriate background 
HED of LA that will equate human equivalent responses based on changes in tissue AA. This 
dietary framework will provide a comparative model for nutritional interventions and therefore 
appropriate translational research. The objective of this application, which is the next step 
toward achieving our overall goal, is to determine the level of LA supplementation that will 
mimic human equivalent responses based on changes in tissue AA.  The central hypothesis, 
based on a mathematical model for allometric scaling, will formulate an appropriate dose of LA 
based on energy consumption that will equate human equivalent responses.  The rationale 
underlying the proposed research comes from a preliminary study in our laboratory looking at 
dietary supplementation of n-3 fatty acids, α- linolenic acid (ALA) and eicosapentanoeic acid 
(EPA) on tissue concentration in rodents. It was found that an increased amount of ALA was 
required in the background rodent diet to mimic human responses. When conducting interspecies 
comparisons, it was found that scaling nutrients in standardized rodent diets based on differences 
in energy intake extrapolated most nutrients to human intakes based on the DRIs. Similarly, the 
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same should hold true when testing the mathematical model for allometric scaling on n-6 
PUFAs.  
 We will test our central hypothesis and achieve the overall objects of this application by 
pursing the following two specific aims: 
1. Determine the extent to which supplementation of HEDs of LA to a human equivalent 
background diet will mimic human responses in tissue AA. 
Working hypothesis: If the model for allometric scaling is formulated correctly, the 
response in rodents should be similar to the responses in humans at equivalent doses. 
2. Determine the extent to which supplementation of AA at HEDs to a human equivalent 
background diet will mimic human responses in tissue AA. 
Working hypothesis: If the model for allometric scaling is formulated correctly the 
response in rodents should be similar to the responses in humans at the same dose. 
  
The proposed research is innovative because there is currently no standardization in 
rodent dietary models or a precise scientific rationale for experimental design. We expect this 
approach to demonstrate that:  1) the mathematical model for interspecies allometric scaling 
appropriately equates human equivalent responses and 2) rodent diets should be based on 
differences in energy consumption.  Application of this knowledge is expected to provide 
translational research for interspecies comparison. 
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Abstract 
It is hypothesized that dietary linoleic acid (LA) promotes chronic and acute diseases by 
enriching tissues with arachidonic acid (AA), its downstream metabolite. However, levels of LA 
in rodent diets are notoriously erratic making interspecies comparisons unreliable. Therefore, the 
ability to extrapolate the biological effects of dietary LA from experimental rodents to humans 
necessitates an allometric scaling model that is rooted within a human equivalent context. To 
determine the physiological response of dietary LA on tissue AA, a mathematical model for 
extrapolating nutrients based on energy was designed to mimic human equivalent doses. 
C57BL/6J mice were divided into 9 groups fed a background diet equivalent to that of the US 
diet with supplemental doses of LA or AA. Changes in the phospholipid fatty acid compositions 
were monitored in plasma and erythrocytes and compared to data from humans supplemented 
with equivalent doses of LA or AA. Increasing dietary LA had little effect on tissue AA, while 
supplementing diets with AA significantly increased tissue AA levels, recapitulating results from 
human trials. Thus, interspecies comparisons for dietary LA between rodents and humans can be 
achieved when rodents are provided human equivalent doses based on differences in metabolic 
activity as defined by energy consumption. 
  
 
List of abbreviations  
AA, arachidonic acid; ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; DRI, dietary 
reference intake; EFA, essential fatty acid; EPA, eicosapentaenoic acid; HED, human equivalent 
dose; LA, linoleic acid; PUFA, polyunsaturated fatty acid 
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2.0 Introduction  
 
As surrogates for human inquisition, animal models reside at the core of medical 
innovation. Through careful environmental control, these genetically similar models facilitate 
therapeutic advancements in the magnitude of human disease. Rodent dietary composition is of 
particular interest in the field of nutrition research as it provides a way to assess the translational 
ability of individual dietary constituents, through appropriate dosing of nutrients, to 
physiological effects observed in humans consuming similar levels of nutrients.  
Dietary profiles of n-6 polyunsaturated fatty acid (PUFA), linoleic acid (LA) and the 
relationship to chronic and acute diseases, in both rodents and humans, appears to lie in tissue 
enrichment of downstream metabolite, arachidonic acid (AA) [1-3]. It is hypothesized that 
dietary metabolism of AA produces bioactive compounds called eicosanoids that are positively 
correlated with the appreciation of tissue AA [4]. While the relationship of AA and eicosanoids 
is well established, the response of dietary LA on changes in tissue levels of AA, within the 
context of a human equivalent diet, remains inconclusive.  
The inconsistent use of n-3 and n-6 essential fatty acids (EFAs) in the background of 
rodent diets is pervasive in the literature [5-10]. These EFAs are important components of the 
Western diet and can impact the AA phospholipid pool when absent or provided at insufficient 
quantities in the diet. Despite suggestions otherwise, a systematic review of the human literature 
reports that increases in dietary LA does not appear to significantly modify AA levels in 
phospholipids of plasma/serum or erythrocytes when supplemented to standard Western diets 
[11].  Therefore, if precise physiological nutrient translation of fatty acids is desired, it may be 
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important for dietary aspects of the rodent model to bear firm resemblance to human dietary 
components.  
This study was designed to necessitate a standard for allometric scaling in animal dietary 
design particularly regarding the relationship of dietary LA and tissue AA. This is the first study 
to examine the physiological response of dietary LA provided at human equivalent supplemental 
doses within the context of a Western background diet, based on a percentage of energy (i.e., 
metabolic activity), on changes in plasma/serum or erythrocyte AA phospholipids. We further 
investigated the potential contribution of dietary AA on tissue AA content within the context of a 
Western-type diet. This mathematical model for allometric scaling should better equate 
interspecies translation and accommodate the differences in metabolic disparity between rodents 
and humans.  
 
 
2.1     Methods  
Animals 
 Sixty-two C57BL/6J male mice (Harlan Laboratory, Indianapolis, IN), 6-7 weeks of age, 
were, randomly assigned to nine dietary groups; 5-7 animals per group housed 2-3 animals per 
cage. They were housed in a temperature controlled room with a 12 hr light-dark cycle. Prior to 
sacrifice, animals were fasted overnight. All animal procedures were approved by the University 
of Tennessee Animal Care and Use Committee in accordance with NIH guidelines.  
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Diets 
All animals were maintained on a control diet for one week prior to being transferred to 
one of the experimental diets or maintained on the control diet. The control diet was based on a 
US17 Monsanto diet with slight modifications in macronutrient distributions (Table 1). The diet 
was designed to mimic the Western diet with the following distribution (% of energy): protein 
16%, carbohydrates 50% and lipids 34% (Research Diets, New Brunswick, NJ) [12]. Within the 
lipid fraction, saturated, monounsaturated and polyunsaturated fats were designed to be provided 
at 13%, 14% and 7% of energy, respectively. The polyunsaturated fats LA, ALA, AA and 
EPA+DHA were provided at 6%, 0.6%, 0.07% and 0.1% of energy, respectively. These levels 
are similar to those suggested in the literature for humans on a Western diet [12-13] and/or 
supported by the DRIs for median daily intakes [14]. AA and EPA+DHA were provided as ethyl 
esters (NuChek Prep, Elysian, MN). Experimental diets remained isocaloric and were formulated 
using the control diet as the background diet containing LA at ~6% of energy with additional 
adjustments in LA content (-2%, +2%, +4%, +6%, +8% of energy) with the addition (or 
subtraction) of sunflower oil (70% w/w LA) at the expense of cocoa butter, palm and trisun oils. 
The diets supplemented with AA were adjusted at the expense of cocoa butter.  
Water and food were provided ad libitum for 21-25 days. Fresh diets were provided daily 
and uneaten food was discarded to minimize oxidation prior to consumption. Fatty acid analysis 
of the diets is presented in (Table 2).  
 
Fatty acid analysis 
Animals were randomized on a 5 day sacrifice cycle. Following 21-25 days on the 
experimental and control diets, 0.5-1.0 ml of whole blood was collected via cardiac puncture 
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under anesthesia (isofluorane inhalation) using a tuberculin syringe with a 25 gauge needle 
containing an anticoagulant (3.8% trisodium citrate). Whole blood was centrifuged at 660 x g for 
4 min at room temperature for separation of plasma and erythrocytes, where each fraction was 
subjected to lipid extraction. Three ml of chloroform-methanol (1:2, v/v) were added to each 
fraction, and lipids were extracted with chloroform (1 ml) plus saline (1 ml), followed by 
chloroform (1 ml) (2x). The pooled chloroform extracts were evaporated and resuspended in a 
small amount of chloroform (~25 µL), and phospholipids were separated via thin layer 
chromatography (TLC) using HPTLC plates precoated with silica gel 60 (Merck, Darmstadt, 
Germany) using a chloroform-methanol (8:1, v/v) solvent system. The phospholipids were 
recovered from the TLC plates and saponified in 0.5 N NaOH and in the presence of BF3 in 
methanol at 86°C. Fatty acids were extracted with equal volumes of hexane (2x) and evaporated 
under nitrogen. Fatty acid methyl esters were resuspended in hexane and analyzed by gas 
chromatography with a Hewlett-Packard 5880 gas chromatograph (Rochester, NY) using a DB23 
capillary column (0.25 mm x 30 m) (J and W Chromatography, Folsom, OH) with hydrogen as 
the carrier gas, with temperature programming from 160°C to 250°C at 3.5°C/min The internal 
standard 1,2 diheptadecanoyl-sn-glycero-3-phosphocholine (17:0) (Avanti Polar Lipids, 
Alabaster, AL) was added to each sample prior to lipid extraction. The fatty acid methyl esters 
were identified by comparing the retention times with those of known standards (NuChek Prep, 
Elysian, MN).  
 
Statistical analysis 
Phospholipid fatty acid content in plasma and erythrocytes were compared across 
treatment groups using a one-way analysis of variance (ANOVA), followed by Tukey‟s Honestly 
 54 
 
 
Significant Difference (HSD) post-hoc test to determine significant differences between groups. 
All data was tested for normality using Kolmogorov-Simimov test (K-S test) and Shaprio-Wilk 
tests, homogeneity by Levene‟s Test of Equality of Variance, and for outliers using boxplot tests. 
The data was evaluated by SPSS 18 statistical package (University of Tennessee, Knoxville, 
TN). Data was considered significant at p < 0.05.  
 
2.2 Results 
Food intake and weight gain were not statistically different between dietary groups (data 
not shown).  
 
Fatty acid composition of plasma phospholipids.   
 The composition of oleic acid and LA in plasma phospholipids tended to reflect 
differences in dietary levels of these fatty acids; however, much of these effects were not 
statistically significant (Table 3). The dietary group with the lowest levels of LA and highest 
levels of oleic acid (group 1) had the lowest levels of LA and highest levels of oleic acid in the 
plasma phospholipids, respectively. The levels of AA did not change in any of the groups with 
increasing or decreasing levels of dietary LA (Table 4). DHA levels were not different among 
groups, with the exception of group 5. When AA was supplemented to the diets, tissue AA levels 
progressively increased in a dose responsive manner at the expense of LA, but tissue DHA levels 
did not change. A summary of the effects of LA and AA supplementation are provided in 
(Figure 1 and Figure 2), respectively.  
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Fatty acid composition of erythrocyte phospholipids 
  The composition of oleic acid and LA in the phospholipids of erythrocytes reflected 
differences in dietary levels of these fatty acids where LA supplementation significantly 
increased LA in the tissues (Table 5 and Figure 3). Levels of dihomo-gamma-linolenic acid 
(20:3n-6) and AA were unaffected by changes in dietary LA. Similarly, DHA content in 
erythrocytes were unaffected by changes in LA intake. When AA was supplemented in the diets, 
tissue AA content progressively increased primarily at the expense of LA, but reductions in 
dihomo-gamma-linolenic acid were also observed (Table 6 and Figure 4). DHA levels were not 
reduced with increasing levels of dietary AA.  
  
2.3 Discussion 
Animal models are not intended to replace humans, but be a substitute that is often better 
controlled for and better able to answer narrow research questions that could not be done, on a 
practical basis, with humans.  A common challenge faced by nutrition researchers who are 
interested in interspecies comparisons is identifying an appropriate background diet and 
appropriate doses for supplemented nutrients.  In order to make these choices, studies have to be 
performed that can demonstrate human equivalent responses to ensure translation between 
species. Without these fundamental studies, no guidelines can be formulated governing scientific 
justification for dosing when extrapolation to humans is desired. Currently, no guidelines exist 
for appropriate dosing of dietary PUFAs for experimental models (i.e., mice, rats) as they relate 
to humans and their intakes. As such, the overall objective of this research was to determine the 
extent to which supplementation of human equivalent doses of LA and AA had on changes in 
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tissue AA content within the context of a Western-type diet using a common experimental rodent 
model and comparing these results to humans. This is the first known study of its kind. 
  Interspecies comparisons were pioneered by Max Kleiber where he described the non-
linear relationship between metabolic rate and body mass as it relates to allometric scaling with 
interspecies comparisons.  This pioneer in the field of animal energetics introduced the concept 
that the relationship between metabolic rate and body weight could be linearized with the 
following equation:  Metabolic rate = a(Body Weight)
0.75
 (where “a” is a proportionality 
constant) [15].  More recently,  Rucker and Storms (2002) elegantly described the pitfalls of 
using differences in body weight as a means of making interspecies extrapolations for 
micronutrients because of these non-linear relationships [16]. They addressed the 
appropriateness of several mathematical approaches to extrapolate nutrient intake between mice 
and humans and suggested food (energy) intake rather than body weight should be used to 
extrapolate nutrients for interspecies comparisons [16-17]. Interestingly, when this concept was 
applied to a variety of standardized semi-purified diets (i.e., AIN76A, AIN93G, AIN93M), 
extrapolations of the nutrients based on energy differentials mimic human equivalent doses. This 
provided the scientific justification for the background diet and doses used in this study. 
With this in mind, we generated a “human equivalent” background diet where the 
macronutrient composition mimicked that of the human diet when based on energy and 
evaluated the impact of dietary LA (4%-14% of energy) and AA (0.08%-1.35% of energy) on 
changes in tissue AA levels in plasma and erythrocyte phospholipids.  These amounts translate 
into human equivalent levels of 9-31 g/d and 0.18-2.7 g/d of LA and AA, respectively, and are 
within those ranges reported in the DRIs for humans and/or used in clinical trials [11, 14].  
Importantly, as opposed to rodent diets that selectively provide only one or two of the essential 
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fatty acids (EFAs) (i.e., corn oil or soybean oil based diets), our background diet contained all 
the major n-6 and n-3 PUFAs found in the human diet (i.e., LA, ALA, AA and long chain n-3 
PUFA). This is critical as all of these fatty acids are found in the Western diet and can have an 
impact on tissue AA levels. For this reason, there has been great interest placed upon n-6 PUFA 
metabolism, particularly when all EFAs are sufficiently provided in the diet at human equivalent 
levels.  
 The rodent model has been the superior target for investigation of specific fatty acids and 
downstream metabolites on tissue fatty acid composition since 1963 when Mohrhauer and 
Holman explored the metabolism of dietary EFAs [7]. In this classic and highly cited paper, 
rodents were initially fed a fat-free diet (i.e. with the exclusion of all EFAs) prior to 
supplementation of LA (ethyl linoleate) up to 5% from energy, where a 721% increase in liver 
AA composition was observed in the highest doses. Other studies recapitulated these earlier 
results when LA was provided to a background diet that lacked nearly all or completely all n-3 
and n-6 PUFAs [9-10]. When LA was increased from nearly 0% of energy to 6-7% of energy in 
rodents, liver AA composition increased 84-173% [6, 8]. Increasing LA from 6% of energy to 
27% of energy (or a human equivalent dose of 59 g/d), resulted in a 134% increase in tissue AA 
composition [5]. The addition of LA at supra-physiological doses (i.e., 17.3% of energy) from a 
background diet containing 7% LA, increased AA content by 375% when no other EFAs were 
provided [10]. However, when more moderate levels of LA were supplemented to a diet 
containing human equivalent levels (i.e., 6.6% to 13.2% of energy), AA content in liver 
phospholipids increased a modest 6% [8]. Notably, tissues have a requirement for unsaturated 
fatty acids for structural function and to help maintain membrane fluidity. When animals are fed 
a diet that exclusively contains a single PUFA (i.e., LA), its selective and robust conversion to a 
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more highly unsaturated form is not surprising. These findings underscore the differential impact 
of dietary LA in rodent diets on changes in tissue AA content when the background diet is 
devoid of LA and/or other PUFAs, or providing LA at doses approaching pharmacological 
levels.  
 What is an appropriate background diet in rodents and what is an appropriate dose of LA 
that has translational ability to humans? This would be dependent upon the human literature; that 
is, what is the effect of LA on changes in tissue AA in individuals consuming a typical Western 
diet? The DRI for LA is 12g/d and 17g/d for women and men, respectively (approximately 6% 
of energy) [14].  In a recent review of the literature, decreasing LA content in the diet up to 90% 
or increasing the levels up to 550% was not associated with changes in AA content in the 
phospholipid pools of plasma/serum or erythrocytes [11]. It is not unreasonable to think, that 
with a background diet containing LA, ALA, AA, and long-chain n-3 PUFAs (i.e., EPA and 
DHA) at typical intakes, modifying LA levels may not influence tissue AA levels in these 
populations. Hence, in order to establish a human equitable response of dietary LA on tissue AA 
composition in the rodent model, it seems best accomplished when all EFAs are present in the 
diet, especially for results that are expected to translate proportionally to humans.   
Increasing LA from 0% to 2% of energy replete tissue pools of n-6 PUFAs by increasing 
AA phospholipid concentrations [18]. Intake of LA above 2-3% of energy in humans is not 
reportedly accompanied by an increase in AA content in plasma or erythrocyte phospholipids 
[11, 19-24], results consistent with our data. Poor conversion rates in humans would account for 
these results where the estimated fractional conversion of LA to AA in adults was between 0.3% 
and 0.6% [25]. In rodents, tracer kinetic analysis demonstrated greater efficiency of C20 fatty 
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acids in conversion to downstream end-products relative to C18 precursors [26]. This would 
imply that feedback inhibition of ∆-6 desaturase, the rate limiting step in the conversion of LA to 
AA, may be responsible. Likewise, the present study reports no significant alteration in 
plasma/serum or erythrocyte AA phospholipids at the lowest supplemental dose of LA (4% of 
energy) or the highest supplemental dose (14% of energy). These results are supported by prior 
rodent dietary studies supplementing LA at similar levels (6.8% and 8.7% of energy) to a 
background diet already containing LA (4.5% of energy) [27-28]. Hence, supplementation of 
HEDs of LA to a background rodent diet consisting of all EFAs found in the human diet, 
(including LA and AA) more accurately correspond to the changes in tissue fatty acid 
composition of AA in humans consuming similar levels [11, 19-21, 24].  
Additionally, our data demonstrates the observable inverse relationship of dietary AA on 
changes in tissue LA within the rodent model. When AA was supplemented to rodents 
consuming a Western-like diet, tissue AA content increased in a dose dependent manner, 
suggesting the lack of changes with LA supplementation was not due to saturation of AA in the 
phospholipid pools analyzed. Likewise, when dietary AA was provided to rodents (mice, 
hamsters) at 1.5-4% of energy, AA content in hepatic phospholipids increased 21-80%; [12, 27-
29]. Similar results were observed in intestines, macrophages, lung, heart, spleen, kidneys, testes 
and platelets [12, 27-28]. These results are comparable to humans [11]; however, the response in 
rodents is more modest than that observed in humans supplemented with AA [11]. Our highest 
supplemented dose of 1.35% of energy (or a HED of 3 g/d) increased phospholipid AA levels in 
plasma/serum by 40%, while providing a dose of 0.75-1.5 g/d in humans increased tissue AA 
content by ~85% [30-31] with a maximum change of 136% at a dose of 6 g/d [32]. Rodents, 
compared to humans, have higher requirements for the more highly unsaturated fatty acid DHA 
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in their tissue phospholipids [33]. This may preclude the need for higher levels of AA in tissues, 
accounting for the more modest effects observed in rodents following AA supplementation. Of 
importance, these changes in AA content were always at the expense of tissue LA, suggesting 
that dietary AA targets the same phospholipid pool occupied by LA [12, 27-28]. This inverse 
relationship between tissue levels of AA and LA following AA supplementation is supported by 
human clinical data [30]. The inverse is not always true. While some studies suggest an inverse 
relationship exists between tissue LA and AA levels when LA is supplemented in the diet [11, 
20, 23], these studies are in the minority.  
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Conclusion 
Currently there are no guidelines providing assistance as to how to formulate a human 
equivalent diet for rodents to improve translation of data to that of humans. The overall objective 
of this research was to test a theoretical model for allometric scaling based on energy differences 
between species. We chose the relationship between dietary LA and its effects on tissue AA 
content as a testable hypothesis. We wanted to determine the extent to which supplementation of 
human equivalent doses of LA and AA had on changes in tissue AA content within the context 
of a Western-type diet using a common experimental rodent model. We proposed that providing 
animals a background diet that mimicked the Western diet with regards to macro- and 
micronutrients and fatty acid profiles, and supplementing LA at human equivalent doses, we 
could observe a human equivalent response with regard to changes in AA levels in plasma/serum 
and erythrocyte phospholipids. Our results recapitulated those in humans and provide support for 
the concept that allometric scaling between species for dietary LA can be accomplished based on 
energy and metabolic differences. It is important to note that these results cannot be extrapolated 
to all tissues.  
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Table 4. Composition of the diets 
 
Dietary Groups 
 
1 2 3 4 5 6 7 8 9 
Diet 
-2%
1
 
LA Control 
+2% 
LA 
+4% 
LA 
+6% 
LA 
+8% 
LA 
+0.23% 
AA 
+0.45% 
AA 
+1.36% 
AA 
 
g/100g 
Protein 17.4 17.4 17.4 17.4 17.4 17.4 17.4 17.4 17.4 
Carbohydrate 54.5 54.5 54.5 54.5 54.5 54.5 54.5 54.5 54.5 
Lipid 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 
 
g/kg 
Casein 150 150 150 150 150 150 150 150 150 
L-Cysteine 3 3 3 3 3 3 3 3 3 
Corn Starch 295 295 295 295 295 295 295 295 295 
Maltodextrin 10 75 75 75 75 75 75 75 75 75 
Sucrose 100 100 100 100 100 100 100 100 100 
Cellulose 50 50 50 50 50 50 50 50 50 
Cocoa Butter, Deodorized 41.6 37.5 33.3 29.1 25.0 21 36.9 35.9 32.1 
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Table 4. Continued 
 
Dietary Groups 
 
1 2 3 4 5 6 7 8 9 
Diet 
-2%
1
 
LA Control 
+2% 
LA 
+4% 
LA 
+6% 
LA 
+8% 
LA 
+0.23% 
AA 
+0.45% 
AA 
+1.36% 
AA 
 
g/100g 
Flaxseed Oil 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 
Palm Oil, Bleached, 
Deodorized 
58.4 52.5 46.8 41.1 35.3 29.5 52.5 52.5 52.5 
Safflower Oil, USP 15.6 28.5 28.5 28.5 28.5 28.5 28.5 28.5 28.5 
Trisun Extra 30 27 24.1 21.1 18.2 15.2 27 27 27 
Sunflower Oil - - 12.8 25.7 38.5 51.3 - - - 
Arachidonic Acid, Ethyl 
Ester 
0.35 0.35 0.35 0.35 0.35 0.35 0.97 1.93 5.8 
Eicosapentaenoic Acid, 
Ethyl Ester 
0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
Docosahexaenoic Acid, 
Ethyl Ester 
0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 
1
% change with regards to energy 
Abbreviations: AA, arachidonic acid; LA, linoleic acid 
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Table 5. The fatty acid composition of the diets  
   Dietary Groups  
 
1 2 3 4 5 6 7 8 9 
Fatty Acids  
-2%
1
 
Control 
2% 4% 6% 8% 0.23% 0.45% 1.36% 
LA LA LA LA LA AA AA AA 
12:0 0.47
2
 0.42 0.39 0.34 0.27 0.26 0.42 0.43 0.42 
14:0 0.69 0.69 0.59 0.56 0.48 0.43 0.63 0.65 0.66 
16:0 26.48 24.69 22.66 20.63 18.71 16.8 24.62 24.31 23.71 
16:1 0.17 0.1 0.15 0.14 0.09 0.09 0.15 0.16 0.16 
18:0 13.13 11.39 11.19 10.08 9.52 8.5 11.69 11.29 10.54 
18:1n-9  42.44 40.44 38.44 36.62 35.00 33.06 40.11 39.79 39.00 
18:2n-6  13.24 18.93 23.23 28.24 32.5 37.39 19.01 19.05 19.08 
18:3n-3  1.78 1.79 1.77 1.8 1.77 1.8 1.78 1.84 1.83 
20:0 0.58 0.54 0.52 0.49 0.48 0.44 0.55 0.55 0.51 
20:1 0.14 0.17 0.15 0.15 0.17 0.14 0.16 0.17 0.14 
20:4n-6  0.21 0.21 0.22 0.22 0.2 0.22 0.55 1.11 3.32 
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Table 5. Continued 
   Dietary Groups  
 
1 2 3 4 5 6 7 8 9 
Fatty Acids  
-2%
1
 
Control 
2% 4% 6% 8% 0.23% 0.45% 1.36% 
LA LA LA LA LA AA AA AA 
20:5n-3  0.09 0.03 0.08 0.07 0.06 0.1 0.05 0.09 0.06 
22:0 0.31 0.31 0.34 0.37 0.42 0.46 0.31 0.29 0.30 
22:6n-3  0.26 0.29 0.27 0.28 0.29 0.31 0.3 0.27 0.27 
1
% change with regards to energy 
2
g/kg diet 
Abbreviations. LA, linoleic  acid; AA, arachidonic acid  
 
 
 
 
 
 
72 
 
Table 6. The fatty acid composition of plasma phospholipids from mice fed linoleic acid supplemented diets  
  Dietary Groups  
Fatty 
Acid  
1 2 3 4 5 6 
-2%  LA
1
  Control  +2%  LA  +4% LA  +6% LA  +8% LA 
16:0  33.54 ± 0.93
2
  34.40 ± 0.80  33.60 ± 1.03  33.25 ± 0.96  35.29 ± 1.15  32.87 ± 0.88  
18:0 13.68 ± 0.55  13.41 ± 0.31  13.07 ± 0.56  13.84 ± 0.61  13.97 ± 0.66  13.49  ± 0.54  
18:1n-9  12.50 ± 0.50  11.69 ± 0.65  9.11 ± 0.64  9.23 ± 0.70  10.29 ± 1.26  10.10 ± 1.18  
18:2n-6  17.80 ± 0.28
a
  19.22 ± 0.42
ab
  20.58 ± 0.44ab  21.86 ± 0.93b  22.15 ± 1.53b  22.46 ± 1.27b  
20:4n-6  13.41 ± 0.40  12.74 ± 0.50  13.94 ± 0.84  13.39 ± 0.63  11.77 ± 0.75  13.10 ± 0.63  
22:6n-3  9.07 ± 0.98
a
  8.54 ± 0.56
ab
  9.09 ± 0.60a  8.43 ± 0.59ab  6.53 ± 0.79b  7.99 ± 0.49ab  
1
%change with regards to energy
 
 
2
Relative abundance (mol%) presented as mean ± SEM  
ab
Means with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s 
honestly significant difference. 
Abbreviations: LA, linoleic acid  
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Table 7. The fatty acid composition of plasma phospholipids from mice fed arachidonic acid supplemented diets  
   Dietary Groups  
Fatty Acid  
2 7 8 9 
Control  +0.23% AA
1  +0.45% AA  +1.36% AA  
16:0  34.40 ± 0.87²  33.62 ± 0.82  33.71 ± 1.07  34.76 ± 0.81  
18:0 13.41 ± 0.34  13.25 ± 0.42  13.34 ± 0.53  12.82 ± 0.36  
18:1n-9  11.69 ± 0.72  11.80 ± 0.83  11.69 ± 0.96  11.53 ± 0.94  
18:2n-6  19.22 ± 0.46
a
  18.88 ± 0.59
ab  17.04 ± 0.28bc  15.47 ± 0.41c  
20:4n-6  12.74 ± 0.54
a
  14.21 ± 0.66
ab  15.94 ± 0.81bc  17.93 ± 1.00c  
22:6n-3  8.54 ± 0.55  8.52 ± 0.52  8.28 ± 0.51  7.51 ± 0.45  
1
%change with regards to energy
 
 
2
Relative abundance (mol%) presented as mean ± SEM  
abc
Means with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s 
honestly significant difference. 
Abbreviations: AA, arachidonic acid  
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Figure 8. Effects of increasing/decreasing dietary linoleic acid on changes in plasma/serum 
phospholipid fatty acid concentration. Mice were fed background diets that mimicked the 
composition of a Western diet with increasing or decreasing levels (% change, based on energy) 
of linoleic acid. The data (mol%) is presented as mean ± SEM. Means with the same superscript 
within the same row (i.e., individual fatty acid) are not statistically different at (p<0.05). 
Abbreviations: LA, linoleic acid 
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Figure 9. Effects of increasing dietary arachidonic acid on changes in plasma/serum 
phospholipid fatty acid concentration. Mice were fed background diets that mimicked the 
composition of a Western diet with increasing levels (% change, based on energy) of arachidonic 
acid. The data (mol%) is presented as mean ± SEM. Means with the same superscript within the 
same row (i.e., individual fatty acid) are not statistically different at (p<0.05). Abbreviations: 
AA, arachidonic acid
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Table 8. The fatty acid composition of erythrocytes phospholipids from diets supplemented with linoleic acid   
  Dietary Groups 
Fatty 
Acid  
1 2 3 4 5 6 
-2% LA
1
  Control  +2% LA  +4% LA  +6% LA  +8% LA  
16:0  34.19 ± 0.66²  34.80 ± 0.63  34.40 ± 0.48  32.81 ± 0.69  34.67 ± 0.62  33.57 ± 0.71  
18:0 13.77 ± 0.30  14.09 ± 0.52  15.45 ± 0.43  14.73 ± 0.45  14.18 ± 0.30  15.35 ± 0.57  
18:1n-9  17.57 ± 0.40
a
  16.63 ± 0.46
a
  14.50 ± 0.34
b  14.61 ± 0.21b  14.48 ± 0.28b  14.09 ± 0.31b  
18:2n-6  10.69 ± 0.13
a
  12.03 ± 0.23
b
  12.23 ± 0.24
b  13.09 ± 0.48bc  13.72 ± 0.28cd  14.52 ± 0.12d  
20:3n-6  1.18 ± 0.33  1.12 ± 0.04  1.22 ± 0.61  1.19 ± 0.08  1.18 ± 0.03  1.18 ± 0.06  
20:4n-6  14.33 ± 0.54  13.60 ± 0.57  14.58 ± 0.45  15.12 ± 0.65  14.56 ± 0.41  13.66 ± 0.74  
22:4n-6  1.40 ± 0.05  1.27 ± 0.13  1.44 ± 0.10  1.62 ± 0.13  1.67 ± 0.06  1.51 ± 0.10  
22:5n-6  0.40 ± 0.05  0.45 ± 0.02  0.50 ± 0.03  0.58 ± 0.10  0.55 ± 0.02  0.47 ± 0.04  
22:5n-3  0.70 ± 0.04  0.64 ± 0.04  0.60 ± 0.03  0.63 ± 0.05  0.60 ± 0.03  0.57 ± 0.05  
22:6n-3  5.76 ± 0.34  5.37 ± 0.49  5.43 ± 0.20  5.64 ± 0.36  5.29 ± 0.27  4.99 ± 0.54  
1
%change with regards to energy
 
 
2
Relative abundance (mol%) presented as mean ± SEM 
abcdMeans with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s 
honestly significant difference. 
Abbreviations: LA, linoleic acid  
77 
 
 
Table 9. The fatty acid composition of erythrocyte phospholipids from  diets supplemented with arachidonic acid  
  Dietary Groups  
Fatty Acid  
2 7 8 9 
Control  +0.23% AA
1
  +0.45% AA  +1.36% AA  
16:0  34.80 ± 0.69²  34.08 ± 0.86  34.43 ± 0.91  35.17 ± 0.95  
18:0 14.09 ± 0.57  14.56 ± 0.31  14.03 ± 0.37  13.95 ± 0.34  
18:1n-9  16.64 ± 0.50  16.49 ± 0.15  15.94 ± 0.29  15.62 ± 0.51  
18:2n-6  12.03 ± 0.25
a
  10.85 ± 0.16
b
  9.65 ± 0.18
c  7.84 ± 0.07d  
20:3n-6  1.12 ± 0.05
a
  0.94 ± 0.01
b
  0.77 ± 0.02
c  0.44 ± 0.01d  
20:4n-6  13.60 ± 0.63
a
  15.13 ± 0.52
ab
  16.77 ± 0.53
bc  18.71 ± 0.93c  
22:4n-6  1.27 ± 0.15
a
  1.54 ± 0.09
ab
  1.90 ± 0.07
bc  2.20 ± 0.11c  
22:5n-6  0.45 ± 0.03
a
  0.49 ± 0.02
ab
  0.57 ± 0.04
ab  0.73 ± 0.05c  
22:5n-3  0.64 ± 0.06  0.64 ± 0.03  0.65 ± 0.03  0.55 ± 0.04  
22:6n-3  5.37 ± 0.54  5.28 ± 0.23  5.29 ± 0.37  4.78 ± 0.40  
1
%change with regards to energy
 
 
2
Relative abundance (mol%) presented as mean ± SEM  
abcd
Means with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s honestly 
significant difference. 
Abbreviations: AA, arachidonic acid  
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Figure 10. Effects of increasing/decreasing dietary linoleic acid on changes in erythrocyte 
phospholipid fatty acid concentration. Mice were fed background diets that mimicked the 
composition of a Western diet with increasing or decreasing levels (% change, based on energy) 
of linoleic acid. The data (mol%) is presented as mean ± SEM. Means with the same superscript 
within the same row (i.e., individual fatty acid) are not statistically different at (p<0.05). 
Abbreviations: LA, linoleic acid. 
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Figure 11. Effects of increasing dietary arachidonic acid on changes in erythrocyte phospholipid 
fatty acid concentration. Mice were fed background diets that mimicked the composition of a 
Western diet with increasing levels (% change, based on energy) of arachidonic acid. The data 
(mol%) is presented as mean ± SEM. Means with the same superscript within the same row (i.e., 
individual fatty acids) are not statistically different at (p<0.05). Abbreviations: AA, arachidonic 
acid. 
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“Don’t be afraid, for I am with you. Don’t be discouraged, for I am your 
God. I will strengthen you and help you. I will hold you up with my 
victorious right hand”  
~ Isaiah 41:10 
“Hard things are put in our way, not to stop us, but to call out our courage 
and strength” 
 
~Unknown Author 
 
“With ordinary talent and extraordinary perseverance, all things are 
attainable”  
 
~Thomas Foxwell Buxton 
 
 
 
